To include your compound in the COVID-19 Resource Center, submit it here.

FX006 regulatory update

Flexion said it now expects to complete Phase III development of FX006 to treat moderate to severe osteoarthritis (OA) knee pain by

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE